Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $21.4 million versus the consensus estimate of $21.43 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.